About Advanced Oncotherapy
Advanced Oncotherapy is a publicly listed company based in London (United Kingdom) founded in 1994. Provider of proton beam therapy system for the treatment of cancer. The company has 157 employees. Its chief executive, as recorded, is Nicolas Serandour. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is ADVANCED ONCOTHERAPY PLC.
Company details
Advanced Oncotherapy was founded in 1994 in London, United Kingdom, and operates in the medical technology sector focused on oncology. Proton beam therapy systems, including the LIGHT product, are developed for cancer treatment. These systems incorporate a proton source, radio-frequency quadrupole, accelerators, nozzle for dose delivery, patient positioning, and imaging components to target tumors precisely. Operations emphasize integration of these elements for clinical applications.
- Headquarters London, United Kingdom
- Employees 157
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website avoplc.com
- Social LinkedIn Facebook
- Legal Name Advanced Oncotherapy Plc
- Date of Incorporation 15 Sep, 2005
- Jurisdiction LONDON, ENGLAND
- Net Profit-$32.47 M (USD)-22as on Dec 31, 2020
- Investors
- Employee Count157
Funding Insights of Advanced Oncotherapy
- Total Rounds 9
- First Round $8.8M
(May 2018)
- Investors Count 1
All 9 funding rounds of Advanced Oncotherapy with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | Post-IPO | – | – | – | |
| Apr 2020 | $17.05M | Post-IPO | – | – | – |
| Nov 2019 | $3.49M | Post-IPO | – | – | – |
| Aug 2019 | $17.52M | Post-IPO | – | – | – |
| May 2019 | $3.05M | Post-IPO | – | – | – |
| Dec 2018 | $12.66M | Post-IPO | – | – | |
| Aug 2018 | $8.4M | Post-IPO | – | – | – |
| May 2018 | $13.27M | Post-IPO | – | – | – |
| May 2018 | $8.8M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Advanced Oncotherapy
Advanced Oncotherapy has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include DNCA Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
DNCA Finance is engaged in asset management and investment services. | 2000 | dnca-investments.com | Paris, France |
Investor details for Advanced Oncotherapy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Advanced Oncotherapy
20 people are tracked at Advanced Oncotherapy (6 in leadership, 14 in team); the tracked headcount is 157.
| Name | Role | Group |
|---|---|---|
Nicolas Serandour | CEO | Leadership |
Julian Tokuta | Director, Supply Chain | Leadership |
Michael Bradfield | Director | Leadership |
Moataz Karmalawy | President | Leadership |
Michel Baelen | Director of Regulatory Affairs and Quality at Advanced Oncotherapy plc and ADAM at CERN in Geneva | Leadership |
Ed Lee | Chief Operating Officer | Leadership |
Margaux Vallé | Project Manager | Team |
Paweł Ptasznik | Control System Engineer C++ | Team |
Olivier Bietzer | System Validation & Clinical Trials Project Manager | Team |
Stephen Gibson | Mechanical Engineer | Team |
Joseph Orrett | Senior Engineer | Team |
Stephen Crewe MSc, Grad IOSH, MCIEH | DIS Health and Safety Manager | Team |
Paolo GRADASSI | Supply Chain Project Engineer | Team |
Theo Rutter | Mechanical Engineer | Team |
Beatriz Conde Fernández | Health Safety and Environment Engineer | Team |
thomas weston | Senior vacuum engineer | Team |
Gerd Eichhorn | Lead System Architect and System Engineering | Team |
Patrick José | Software Build and Release Engineer | Team |
Skordis Eleftherios | Senior Radiation Transport Engineer | Team |
Hycham Aboutaleb, PhD ✅ | Deputy Group Leader of the Systems Engineering group | Team |
Complete people profiles for Advanced Oncotherapy
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Advanced Oncotherapy
4 dated milestones of Advanced Oncotherapy across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Advanced Oncotherapy is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $8.8M.
- Funding Latest funding round, Post-IPO,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Advanced Oncotherapy
Complete news archive for Advanced Oncotherapy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Advanced Oncotherapy
Advanced Oncotherapy was founded in 1994 and raised its 1st funding round 24 years after it was founded.
Advanced Oncotherapy is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Nicolas Serandour is the CEO of Advanced Oncotherapy, as recorded in our data.
Advanced Oncotherapy has 157 employees.
Advanced Oncotherapy was founded in 1994 in London, United Kingdom, and operates in the medical technology sector focused on oncology. Proton beam therapy systems, including the LIGHT product, are developed for cancer treatment. These systems incorporate a proton source, radio-frequency quadrupole, accelerators, nozzle for dose delivery, patient positioning, and imaging components to target tumors precisely. Operations emphasize integration of these elements for clinical applications.
Advanced Oncotherapy has 1 investor. Key investors include DNCA Finance.
Advanced Oncotherapy operates through Advanced Oncotherapy Plc.